The endpoint date matters
OASIS 4 randomized 307 adults with overweight or obesity without diabetes to daily oral semaglutide 25 mg or placebo, alongside lifestyle intervention. The trial lasted 71 weeks, with its primary efficacy assessment at week 64. It was double-blind and funded by Novo Nordisk. [1]
This is an example of why a trial’s total duration and its primary measurement date should not be used interchangeably. A headline can accurately mention one while leaving the other unclear. When comparing studies, record the date at which the cited result was actually assessed.
What the trial reported
Estimated average weight change at week 64 was −13.6% with oral semaglutide and −2.2% with placebo. A weight-related physical-function score also improved more with active treatment. Gastrointestinal adverse events occurred in 74.0% versus 42.2%. [1]
The physical-function outcome broadens the report beyond a scale reading, but it remains a particular questionnaire measure. It should not be rewritten as a guarantee of better fitness or a specific change in daily activities. The reader benefits from knowing what was measured as well as which direction it moved.
A lower trial dose does not establish equivalence
OASIS 4 and OASIS 1 tested different oral target regimens in separate studies. Their results cannot prove that the regimens are interchangeable or that one is sufficient for a particular person. Similar ingredient names and different numerical doses do not replace a direct comparative design.
The study also does not answer whether a person should change from an injection to a tablet. A switching question includes prior treatment, clinical circumstances and the actual products available. Those details require a clinician’s assessment rather than an inference from two separate trial averages.
The allocation ratio also explains why the active and placebo groups had different sizes. Unequal group sizes do not by themselves indicate biased assignment. The important questions are how randomization occurred and how the analysis handled the resulting data, not whether the columns contain exactly the same number of participants.
Read the paper alongside the actual product information
When a provider cites OASIS 4, ask whether the product being offered is the studied formulation and whether the current prescribing information matches the intended use. Publication demonstrates what researchers tested; it is not by itself proof of present approval, local availability or plan coverage.
Our coverage guide helps separate an insurer’s answer from a provider’s marketing claim. Use the cost tool only after medication and service charges are established. The practical value of oral research is greater when the formulation, endpoint and purchasing assumptions are all made explicit.